Anti–Programmed Death 1 (PD-1) Antibodies and the Pancreas: A Diabetic Storm Ahead?

Nivolumab, a human IgG4 programmed death 1 immune checkpoint-inhibitor antibody, disrupts PD-1-mediated signaling and restores antitumor immunity. Many recent studies have emphasized the importance of anti-PD-1 antibodies to improve survival outcomes among patients with advanced melanoma or lung can...

Full description

Saved in:
Bibliographic Details
Published inDiabetes care Vol. 41; no. 3; pp. 638 - 639
Main Authors Marchand, Lucien, Thivolet, Arnaud, Saintigny, Pierre, Fabien, Nicole, Vouillarmet, Julien, Thivolet, Charles
Format Journal Article
LanguageEnglish
Published United States American Diabetes Association 01.03.2018
Subjects
Antibodies
Diabetes
Diabetes mellitus
Immunity
Immunoglobulin G
Immunoglobulins
Immunotherapy
Insulin
Life Sciences
Lung cancer
Melanoma
Monoclonal antibodies
Pancreas
Patients
PD-1 protein
Side effects
Targeted cancer therapy
pathogenesis
Endocrinology & Metabolism
Online AccessGet full text
ISSN0149-5992
1935-5548
1935-5548
0149-5992
DOI10.2337/dc17-2243

Cover

More Information
Summary:Nivolumab, a human IgG4 programmed death 1 immune checkpoint-inhibitor antibody, disrupts PD-1-mediated signaling and restores antitumor immunity. Many recent studies have emphasized the importance of anti-PD-1 antibodies to improve survival outcomes among patients with advanced melanoma or lung cancer. Several endocrinological side effects have been reported and a few patients developed insulin-requiring diabetes. Here, Marchand et al examine the case of a 55-year-old Caucasian man with advanced pulmonary pleomorphic carcinoma and has a fulminant diabetes and hypophysitis after nine courses of nivolumab.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0149-5992
1935-5548
1935-5548
0149-5992
DOI:10.2337/dc17-2243